HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Einhorn, L. H. Search for Related Content PubMed PubMed Citation Articles by Einhorn, L. H.

The Annals of Thoracic Surgery, Vol 46, 362-365, Copyright © 1988 by The Society of Thoracic Surgeons

ARTICLES

Neoadjuvant therapy of stage III non-small cell lung cancer

LH Einhorn
Department of Medicine, Indiana University Medical Center, Indianapolis 46223.

During the past several years, there has been a resurgence of interest in preoperative or postoperative chemotherapy in patients with Stage III lung cancer. The staging system for lung cancer has recently been modified, and at the present time Stage III disease is now subdivided into Stage III-A (potentially surgically resectable for cure) and Stage III-B (unresectable). This article will review five recently completed studies utilizing neoadjuvant therapy in various types of Stage III lung cancer. The thoracic surgeon is faced with the dilemma of reviewing this literature and trying to make a conclusion as to what is appropriate therapy for Stage III disease. Unquestionably, neoadjuvant therapy appears to increase the resectability rate in Stage III-A disease and can make some Stage III-B patients anatomically resectable. It is hoped that future well-designed phase III studies can be accomplished in Stages III-A and III-B disease so that we can determine whether neoadjuvant chemotherapy is or is not beneficial for these patients.

This article has been cited by other articles:

				H. Wada, R. Miyahara, F. Tanaka, and S. Hitomi Postoperative adjuvant chemotherapy with PVM (Cisplatin+Vindesine+Mitomycin C) and UFT (Uracil+Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial Eur. J. Cardiothorac. Surg., April 1, 1999; 15(4): 438 - 443. [Abstract] [Full Text] [PDF]

				L. H. Einhorn Neoadjuvant and Adjuvant Trials in Non-Small Cell Lung Cancer Ann. Thorac. Surg., January 1, 1998; 65(1): 208 - 211. [Abstract] [Full Text] [PDF]